Table 4.
N | No. LC | Duration (yr) | LCDR | 95% CI | NND | |
---|---|---|---|---|---|---|
P-IELCAP cohort* | ||||||
P-IELCAP | 1,696 | 25 | 3.47 | 0.43 | 0.29–0.63 | 235 |
NLST | 660 | 13 | 3.80 | 0.52 | 0.30–0.89 | 193 |
NLST/E | 883 | 22 | 3.47 | 0.72 | 0.47–1.09 | 139 |
P-IELCAP(E) | 394 | 15 | 3.07 | 1.24 | 0.75–2.06 | 81 |
PLuSS cohort* | ||||||
PLuSS | 3,437 | 62 | 4.20 | 0.43 | 0.34–0.55 | 233 |
NLST | 2,047 | 53 | 5.41 | 0.48 | 0.37–0.63 | 209 |
NLST/E | 2,514 | 59 | 5.31 | 0.44 | 0.34–0.57 | 226 |
PLuSS(E) | 1,433 | 40 | 5.71 | 0.49 | 0.36–0.67 | 205 |
Definition of abbreviations: CI = confidence interval; (E) suffix = limitation of annual low-dose chest computed tomography in P-IELCAP and PLuSS to individuals with emphysema; LCDR = lung cancer detection rate; NLST = National Lung Screening Trial; NLST/E = extended NLST subcohort including individuals with emphysema independent of NLST; No. LC = number of lung cancers; NND = number of people needed to be screened in a year to detect one lung cancer; P-IELCAP = Pamplona International Early Lung Cancer Action Program; PLuSS = Pittsburgh Lung Screening Study.
Only lung cancers diagnosed at or after the second round of screening (incident cancers) are considered.